TheraVectys
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
TheraVectys - overview
Established
2005
Location
Paris, -, France
Primary Industry
Biotechnology
About
Based in Paris, France and founded in 2005, TheraVectys is a biotechnology company that develops vaccines for cancer and other infectious diseases such as HIV, hepatitis, and malaria. The company was founded by Ye Tian, a seasoned investor. Pierre Charneau, head of the Molecular Virology and Vaccinology Laboratory at the Pasteur Institute, Paris, France. In September 2012, TheraVectys raised EUR 7.
5 million (USD 9. 6 million) in Series C funding from individual investors. The company provides a lentiviral vector platform that helps the body prepare against infectious diseases. TheraVectys's goal is to fundamentally change global health through the development of prophylactic and therapeutic vaccines based on our lentiviral vectors.
Current Investors
OSEO, Tethys Bioscience, FGP Capital
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Epidemiology, Pharmaceutical Research & Development
Website
www.theravectys.com
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.